ommunity oncologists, and we are very pleased to have been selected as their preferred comprehensive genomic profiling services partner," commented Kevin Krenitsky, M.D., chief commercial officer and senior vice president, international strategy, Foundation Medicine. "Our mission at Foundation Medicine is to p

ves as further validation of the clinical utility of a treatment plan informed by comprehensive genomic profiling of a patient's unique cancer: said Kevin Krenitsky, MD, chief commercial officer of Foundation Medicine. Priority Health's leadership in recognizing important innovations to advance patient care mar